semaglutide cardiovascular outcomes news 2025 In patients with cardiovascular disease and overweight or obesity but no Oral Semaglutide and Cardiovascular Outcomes

Dizziness during semaglutide treatment often stems from rapid blood sugar drops, dehydration, or dose escalation

Cotizacin y grfico ROUNDHILL GLP-1 &amp

So, it's infuriating to get ads like this

Understanding the mechanism and implementing practical solutions helps minimize this common side effect during weight loss therapy

Medicaid coverage for GLP-1 drugs varies significantly by state and plan, with most programs requiring prior authorization and medical documentation of BMI, comorbidities, or failed weight loss attempts

Patients switch because of efficacy, tolerability, access, cost, insurance coverage, or newer options becoming available